Literature DB >> 3714967

Relation between signs and symptoms in Paget's disease of bone.

H I Harinck, O L Bijvoet, C J Vellenga, H J Blanksma, W B Frijlink.   

Abstract

The relation between signs and symptoms of Paget's disease of bone was studied in 180 patients consecutively submitted for treatment. In these patients 826 lesions were identified by scintigraphy. The intensity of scintigraphic uptake was correlated with long-term calcium uptake in bone. The frequency distribution of lesions over the patients was compatible with a 65 per cent chance of local disease once the patient had been exposed to an extraneous agent. The spatial distribution within a skeleton was related to the local density of the osteoclast population. The particular frequency distribution resulted in a log-normal distribution diagram for anatomical spread. Within lesions, increases in numbers of osteoclasts and osteoblasts were proportional and these too had a log-normal distribution. Increases of alkaline phosphatase levels and hydroxyproline excretion were closely related and reflected anatomical spread on the one hand and local activity on the other. They were also closely correlated with overall calcium fluxes. It was shown that alkaline phosphatase is the more sensitive and hydroxyproline the more accurate of the biochemical signs. Maximum values, corresponding to total skeletal disease, were approximately 25 times the upper limit of normal. Equilibrium between bone formation and resorption was not always maintained. There were, indeed, wide variations of urinary calcium, which were significantly related to the difference between bone formation and resorption, but the extracellular calcium homeostasis was generally maintained. This may explain the frequent occurrence of normocalcaemic and hypercalcaemic hyperparathyroidism. The hypercalciuria constitutes an additional risk for urolithiasis in men. The most frequent complaint was pain (86 per cent). Extent of lesions was important, but a major decisive factor was the specific nature of the bone affected. The findings allowed assessment of the relative importance of the various signs, symptoms and locations as criteria of disease severity and as indications for treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3714967

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  7 in total

1.  Paget's disease of bone.

Authors:  R Smith
Journal:  BMJ       Date:  1992-12-05

Review 2.  Paget's Disease of Bone.

Authors:  Luigi Gennari; Domenico Rendina; Alberto Falchetti; Daniela Merlotti
Journal:  Calcif Tissue Int       Date:  2019-01-23       Impact factor: 4.333

3.  Clinical efficacy of oral risedronate therapy in Japanese patients with Paget's disease of bone.

Authors:  Masaya Ohara; Yasuo Imanishi; Yuki Nagata; Akira Ishii; Ikue Kobayashi; Katsuhito Mori; Manabu Ito; Takami Miki; Yoshiki Nishizawa; Masaaki Inaba
Journal:  J Bone Miner Metab       Date:  2014-10-16       Impact factor: 2.626

4.  Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).

Authors:  H I Harinck; S E Papapoulos; H J Blanksma; A J Moolenaar; P Vermeij; O L Bijvoet
Journal:  Br Med J (Clin Res Ed)       Date:  1987-11-21

Review 5.  Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  A Fitton; D McTavish
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

Review 6.  Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment.

Authors:  C Gennari; R Nuti; D Agnusdei; A Camporeale; G Martini
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

Review 7.  Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.